WEBSITE BSE:544742 NSE: SAIPARENT Inc. Year: 2001 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:57
Sai Parenterals Limited is an India based pharmaceutical company engaged in the manufacturing of sterile injectable formulations. The company focuses on producing a wide range of products including small volume parenterals large volume parenterals and dry powder injections catering to both domestic and international markets. It operates manufacturing facilities compliant with regulatory standards and serves hospitals healthcare institutions and pharmaceutical distributors. Sai Parenterals has developed capabilities in contract manufacturing and...Read More
Sai Parenterals Limited is an India based pharmaceutical company engaged in the manufacturing of sterile injectable formulations. The company focuses on producing a wide range of products including small volume parenterals large volume parenterals and dry powder injections catering to both domestic and international markets. It operates manufacturing facilities compliant with regulatory standards and serves hospitals healthcare institutions and pharmaceutical distributors. Sai Parenterals has developed capabilities in contract manufacturing and third party production which supports its growth and market reach. The company benefits from rising demand for injectable drugs driven by increasing healthcare access and hospital based treatments in India and globally. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹2121 Cr.
Stock P/E 147
P/B 4.2
Current Price ₹480.1
Book Value ₹ 115.6
Face Value 5
52W High ₹523.4
Dividend Yield 0%
52W Low ₹ 400
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Net Sales | 97 | 154 | 163 | |
| Other Income | 0 | 2 | 1 | |
| Total Income | 97 | 155 | 164 | |
| Total Expenditure | 78 | 122 | 124 | |
| Operating Profit | 19 | 33 | 40 | |
| Interest | 6 | 11 | 12 | |
| Depreciation | 6 | 9 | 8 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | |
| Profit Before Tax | 7 | 13 | 20 | |
| Provision for Tax | 3 | 4 | 5 | |
| Profit After Tax | 4 | 8 | 14 | |
| Adjustments | 0 | 0 | -0 | |
| Profit After Adjustments | 4 | 9 | 14 | |
| Adjusted Earnings Per Share | 3.1 | 3.4 | 5.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 6% | 0% | 0% | 0% |
| Operating Profit CAGR | 21% | 0% | 0% | 0% |
| PAT CAGR | 75% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 17% | 16% | 16% | 16% |
| ROCE Average | 17% | 15% | 15% | 15% |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Shareholder's Funds | 31 | 75 | 94 |
| Minority's Interest | 0 | 2 | 2 |
| Borrowings | 26 | 39 | 14 |
| Other Non-Current Liabilities | 0 | -0 | -0 |
| Total Current Liabilities | 77 | 153 | 162 |
| Total Liabilities | 134 | 267 | 272 |
| Fixed Assets | 44 | 70 | 53 |
| Other Non-Current Assets | 8 | 10 | 19 |
| Total Current Assets | 82 | 187 | 200 |
| Total Assets | 134 | 267 | 272 |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Opening Cash & Cash Equivalents | 10 | 2 | 4 |
| Cash Flow from Operating Activities | -13 | -30 | 33 |
| Cash Flow from Investing Activities | -19 | -46 | 0 |
| Cash Flow from Financing Activities | 24 | 79 | -36 |
| Net Cash Inflow / Outflow | -8 | 2 | -2 |
| Closing Cash & Cash Equivalent | 2 | 4 | 2 |
| # | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Earnings Per Share (Rs) | 3.06 | 3.35 | 5.33 |
| CEPS(Rs) | 7.11 | 6.73 | 8.5 |
| DPS(Rs) | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 22.02 | 28.13 | 35.19 |
| Core EBITDA Margin(%) | 19.15 | 20.54 | 24.15 |
| EBIT Margin(%) | 13.4 | 15.4 | 19.51 |
| Pre Tax Margin(%) | 7.49 | 8.17 | 12.21 |
| PAT Margin (%) | 4.52 | 5.47 | 8.85 |
| Cash Profit Margin (%) | 10.51 | 11.6 | 13.88 |
| ROA(%) | 3.27 | 4.19 | 5.35 |
| ROE(%) | 13.9 | 15.87 | 17.15 |
| ROCE(%) | 12.97 | 16.14 | 16.71 |
| Receivable days | 230.8 | 223.46 | 283.79 |
| Inventory Days | 49.73 | 59.82 | 98.79 |
| Payable days | 140.32 | 144.13 | 215.25 |
| PER(x) | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.78 | 0.83 | 0.64 |
| EV/Core EBITDA(x) | 4.02 | 3.86 | 2.63 |
| Net Sales Growth(%) | 0 | 58.85 | 6.08 |
| EBIT Growth(%) | 0 | 82.49 | 34.38 |
| PAT Growth(%) | 0 | 92.3 | 71.44 |
| EPS Growth(%) | 0 | 9.6 | 59.09 |
| Debt/Equity(x) | 2.18 | 1.59 | 1 |
| Current Ratio(x) | 1.07 | 1.23 | 1.23 |
| Quick Ratio(x) | 0.9 | 0.98 | 0.92 |
| Interest Cover(x) | 2.27 | 2.13 | 2.67 |
| Total Debt/Mcap(x) | 0 | 0 | 0 |
| # | Mar 2026 |
|---|---|
| Promoter | 51.16 |
| FII | 5.73 |
| DII | 12.86 |
| Public | 30.26 |
| Others | 0 |
| Total | 100 |
| # | Mar 2026 |
|---|---|
| Promoter | 2.26 |
| FII | 0.25 |
| DII | 0.57 |
| Public | 1.34 |
| Others | 0 |
| Total | 4.42 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
